InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Vera Therapeutics, Inc.

VERA Clue Score36
United States Fiscal year ends December CIK 0001831828
$29.88 +0.50% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $29.88 +85.71% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 14 May 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2020Operating income−52.2Net income−53.4Fiscal year 2021Operating income−34.4Net income−32.6EPS, diluted−2.43Fiscal year 2022Operating income−90.9Net income−89.1EPS, diluted−3.35Fiscal year 2023Operating income−102.0Net income−96.0EPS, diluted−2.25Fiscal year 2024Operating income−167.2Net income−152.1EPS, diluted−2.75Fiscal year 2025Operating income−315.5Net income−299.6EPS, diluted−4.66
FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −52.2 −34.4 −90.9 −102.0 −167.2 −315.5
Net income −53.4 −32.6 −89.1 −96.0 −152.1 −299.6
Growth
EPS, diluted n/a −2.43 −3.35 −2.25 −2.75 −4.66

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−34.8Capital expenditure−0.1Free cash flow−34.9Fiscal year 2021Operating cash flow−23.7Capital expenditure0.0Free cash flow−23.7Fiscal year 2022Operating cash flow−67.6Capital expenditure−0.1Free cash flow−67.7Fiscal year 2023Operating cash flow−92.2Capital expenditure−0.1Free cash flow−92.2Buybacks0.0Fiscal year 2024Operating cash flow−134.7Capital expenditure−1.0Free cash flow−135.7Buybacks−0.0Fiscal year 2025Operating cash flow−241.1Capital expenditure−0.6Free cash flow−241.7Buybacks0.0
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −34.8 −23.7 −67.6 −92.2 −134.7 −241.1
Capital expenditure −0.1 0.0 −0.1 −0.1 −1.0 −0.6
Free cash flow −34.9 −23.7 −67.7 −92.2 −135.7 −241.7
Growth
Buybacks n/a n/a n/a 0.0 −0.0 0.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2020Cash53.7Total debt0.0Net cash (debt)53.7Shareholders’ equity−89.3Fiscal year 2021Cash79.7Total debt4.9Net cash (debt)74.8Shareholders’ equity69.6Debt to equity0.07Fiscal year 2022Cash43.5Total debt24.8Net cash (debt)18.6Shareholders’ equity76.9Debt to equity0.32Fiscal year 2023Cash45.7Total debt49.9Net cash (debt)−4.2Shareholders’ equity101.7Debt to equity0.49Fiscal year 2024Cash92.6Total debt50.7Net cash (debt)42.0Shareholders’ equity577.2Debt to equity0.09Fiscal year 2025Cash354.7Total debt74.8Net cash (debt)279.9Shareholders’ equity604.5Debt to equity0.12
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 53.7 79.7 43.5 45.7 92.6 354.7
Total debt 0.0 4.9 24.8 49.9 50.7 74.8
Net cash (debt) 53.7 74.8 18.6 −4.2 42.0 279.9
Shareholders’ equity −89.3 69.6 76.9 101.7 577.2 604.5
Debt to equity n/a 0.07 0.32 0.49 0.09 0.12

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −46.9% −115.8% −94.4% −26.4% −49.6%
−97.9% −38.9% −67.8% −54.7% −23.2% −40.8%
Balance and payout
n/a 0.07 0.32 0.49 0.09 0.12
7.9% 16.9% 41.5% 42.1% 12.0% 17.7%